Abstract The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus has challenged health-care systems and physicians worldwide to aim to produce the most effective care to their patients with an evolving understanding of this distinctive infective agent. Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. This article aimed to evaluate the efficacy and safety of aspirin in patients with COVID-19. This illness and its worldwide impact have sparked tremendous interest within the medical specialty, pathologic process, and clinical consequences of COVID-19. Our goal is to produce steerage to the employment of antithrombotic and antiplatelet therapies in patients with far-famed or suspected COVID-19.This accumulating body of proof has targeted around case series and sometimes empiric therapies as controlled trials are simply obtaining afoot. What’s clear is that patients seem to be at higher risk for thrombotic illness states together with acute coronary syndrome (ACS), blood vessel occlusion (VTE) like deep vein occlusion (DVT) or embolism (PE), or stroke. Patients with underlying disorder also are at higher risk for morbidity and mortality if infected. These patients are normally treated with medical aid and/or antiplatelet medications and fewer normally lysis throughout hospitalization, probably with profit however the management of those medications is troublesome in probably critically sick patients. This article may be acquired to get overview of antithrombotic and NSAIDS in treatment of Covid-19.
Keywords Covid-19, Acute coronary syndrome, rivaroxaban, aspirin, anticoagulant, Antiplatelet.